Literature DB >> 3107809

Interactions of cis-diamminedichloroplatinum(II) with 1-beta-D-arabinofuranosylcytosine in LoVo colon carcinoma cells.

R J Fram, N Robichaud, S D Bishov, J M Wilson.   

Abstract

Prior reports demonstrated more than additive cytotoxic effects of cis-diamminedichloroplatinum(II) (CDDP) and 1-beta-D-arabinofuranosylcytosine (ara-C) in LoVo colon carcinoma cells. We have extended these findings by analyzing mechanisms that may underlie the effect of ara-C on CDDP-induced cytotoxicity. In contrast to a previous study, ara-C neither enhances DNA interstrand cross-link formation by CDDP nor affects the excision of platinum from DNA. Features peculiar to ara-C, such as its misincorporation into DNA, probably contribute since more than additive cytotoxic effects do not occur by combinations of CDDP with inhibitors of DNA synthesis that are not incorporated into DNA. Also, while ara-C does not significantly enhance the degree of inhibition of DNA synthesis caused by CDDP, the recovery of DNA synthesis after drug removal is significantly slowed when cells are exposed to both drugs. These findings contrast with those obtained with CDDP and aphidicolin (the latter agent resembles ara-C in competing with dCTP for binding to DNA polymerase alpha but, unlike ara-C, is not incorporated into DNA). Lastly, ara-C is incorporated into LoVo cell DNA undergoing replicative synthesis as well as into DNA undergoing repair synthesis after CDDP-induced induced DNA damage.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107809

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.

Authors:  J L Abbruzzese; P Frost
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.

Authors:  J H Marsh; W Kreis; B Barile; S Akerman; P Schulman; S L Allen; L C DeMarco; M W Schuster; D R Budman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 3.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.